Navigation Links
Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox
Date:11/6/2009

RESEARCH TRIANGLE PARK, N.C., Nov. 6 /PRNewswire/ -- Chimerix, Inc., a biopharmaceutical company advancing orally-available antiviral therapeutics to address life-threatening diseases, presented updates on the development of the company's lead antiviral compound, CMX001, to the World Health Organization (WHO) and the Global Health Security Initiative (GHSI). CMX001 is a broad-spectrum antiviral agent being developed for the treatment of smallpox, as well as other serious viral infections.

Randall Lanier, Ph.D., Director of Virology for Chimerix, spoke at the WHO 11th meeting of the Advisory Committee on Variola Virus Research in Geneva, Switzerland, on Wednesday, November 4, 2009. George Painter, Ph.D., Chimerix's Chief Executive Officer, spoke to the GHSI's Public Health Emergency Medical Countermeasures Workshop on Thursday, November 5, 2009. Dr. Painter's and Dr. Lanier's presentations included updates on the development of CMX001 for both biodefense and commercial uses as a broad-spectrum antiviral against double-stranded DNA viruses, including variola, as well as recent uses of the product under Emergency Investigational New Drug (E-IND) protocols against adenovirus and progressive vaccinia in immune-compromised patients.

Dr. Painter said, with regard to both the WHO and GHSI presentations, "We are quite pleased with the progress of CMX001 and look forward to working with both the U.S. and international public health and transplant communities to continue to move the product toward regulatory approval."

CMX001 combines Chimerix's PIM (phospholipid intramembrane microfluidization) Conjugate Technology with cidofovir, an approved antiviral agent, with the aim of creating a well-tolerated and highly potent new chemical entity with broad-spectrum antiviral activity. CMX001 is initially being developed for both commercial and medical preparedness uses. Chimerix is currently conducting clinical trials of CMX001 for the
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
2. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
3. Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain
4. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
5. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
6. Alliance Pharmaceutical Corp. Updates Oxygent(TM) Clinical Development Plan
7. Imaging Diagnostic Systems Updates PMA Filing Status for the New CT Laser Breast Imaging System
8. BioCryst Updates Peramivir Clinical Development Plan
9. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
10. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
11. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... , July 13, 2014  Eli Lilly and ... results from its non-clinical study in genetically engineered ... of the beta-amyloid antibody N3pG and beta-secretase inhibitor ... was more effective in removing clumps of amyloid-beta ... is thought to lead to Alzheimer,s disease (AD) ...
(Date:7/11/2014)... 11, 2014 The consumer marketing playbook ... industry sectors to better identify winning tools and ... engage with and understand consumers, as new technologies ... critical purchasing decisions. According to ... one area where organizations can observe a deep ...
(Date:7/11/2014)... According to a new ... Material, Application (Healthcare, Homeland security, Industrial application, Nuclear ... Hand-Held Instruments, Fixed, and Installed Instruments) & Geography ... by MarketsandMarkets, the Scintillator Market is expected to ... to 2020, and reach $479.16 Million in 2020. ...
Breaking Medicine Technology:New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 3New Technologies Transforming Consumer Marketing Research Playbook 2Scintillator Market will be worth $479.16 Million by 2020 2Scintillator Market will be worth $479.16 Million by 2020 3Scintillator Market will be worth $479.16 Million by 2020 4
... Israel, November 12 Surgeons,at the University of ... can be converted to an endovascular simulator,(ANGIO Mentor(TM), ... agreed" that the simulation improved the operative flow,increased ... operative and fluoroscopy time and the amount of ...
... New Data Suggesting Need for Improved ... Annual Meeting -, EXTON, Pa., Nov. 12 ViroPharma ... from its ongoing,open-label study, showing that in this study Cinryze(TM) ... (HAE),attacks seen in the study through the date of analysis. ...
Cached Medicine Technology:Vascular Surgeons Agree: Case Rehearsal Improves Outcomes 2ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema 2ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema 3ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema 4ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema 5ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema 6
(Date:7/13/2014)... The report “Micronutrient Market by ... (Chelated & Non Chelated), Application Mode (Soil, Foliar, ... and Forecast to 2018” defines and segments the ... forecasting of the global value and volume for ... restraining factors for the global agriculture micronutrients market ...
(Date:7/13/2014)... 13, 2014 A Massachusetts couple who ... cancer risks associated with power morcellators ( http://www.gynecaremorcellatorlawsuit.com/ ) ... to federal regulators, as they presented poignant testimony on ... Drug Administration (FDA) advisory panel meeting convened to address ... the Rochester Democrat and Chronicle, Dr. Hooman Noorchashm and ...
(Date:7/13/2014)... Recently, 2014QuinceaneraDresses.com, the distinguished special ... new range of gorgeous Quinceanera dresses . ... for elegant Quinceanera outfits is huge. Therefore, 2014QuinceaneraDresses.com ... the company’s newly released dresses are made according ... elegant and vivid. , It is worthy ...
(Date:7/13/2014)... imaging device developed at Cedars-Sinai can provide early ... brain and are a classic sign of Alzheimer,s ... a clinical trial in Australia. , The researchers ... oral presentation at the Alzheimer,s Association International Conference ... by conference organizers to participate in a "breaking ...
(Date:7/13/2014)... 13, 2014 Celebrity fitness trainer and ... a promotional partnership with Aqua Health Labs for their ... EPA supplement . The collaboration was recently announced live ... fitness trainer , actor, model, and a two time ... A-List celebrities, he has prepared stars including Demi Moore, ...
Breaking Medicine News(10 mins):Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 2Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 3Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 4Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 2Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 3Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 4Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 3Health News:Celebrity Fitness Expert Supports Revolutionary New Health Supplement 2
... states, CDC report shows, , TUESDAY, March 2 (HealthDay ... States, a new government study shows, but certain states ... The overall rate of asthma is currently estimated to ... about 0.5 percent every three years. But, the report ...
... , ... ... ... ...
... , ... ... ... ...
... ... ... , ... , , , ...
... ... into the exploding field of neuroscience, what this means for leadership and how it ... to motivate and generate transformation in organisations – all leading to better organisations and ... ...
... ... Software Developers. , ... RSA San Francisco, CA (PRWEB) March 2, 2010 -- GlobalSign Inc ... in supplying Digital Identities used to authenticate the publisher of software and produce ...
Cached Medicine News:Health News:Asthma Rates Rising Across the U.S. 2Health News:Asthma Rates Rising Across the U.S. 3Health News:Yongye International to Present at Rodman & Renshaw Annual China Investment Conference 2Health News:Yongye International to Present at Rodman & Renshaw Annual China Investment Conference 3Health News:Yongye International to Present at Rodman & Renshaw Annual China Investment Conference 4Health News:Yongye International to Present at Rodman & Renshaw Annual China Investment Conference 5Health News:Yongye International to Present at Rodman & Renshaw Annual China Investment Conference 6Health News:Yongye International to Present at Rodman & Renshaw Annual China Investment Conference 7Health News:Yongye International to Present at Rodman & Renshaw Annual China Investment Conference 8Health News:Yongye International to Present at Rodman & Renshaw Annual China Investment Conference 9Health News:ReportsandReports : The Gastrointestinal Market Outlook to 2014: Market Dynamics, Competitive Landscape, Emerging Therapies 2Health News:ReportsandReports : The Gastrointestinal Market Outlook to 2014: Market Dynamics, Competitive Landscape, Emerging Therapies 3Health News:ReportsandReports : The Gastrointestinal Market Outlook to 2014: Market Dynamics, Competitive Landscape, Emerging Therapies 4Health News:ReportsandReports : The Gastrointestinal Market Outlook to 2014: Market Dynamics, Competitive Landscape, Emerging Therapies 5Health News:ReportsandReports : The Gastrointestinal Market Outlook to 2014: Market Dynamics, Competitive Landscape, Emerging Therapies 6Health News:ReportsandReports : The Gastrointestinal Market Outlook to 2014: Market Dynamics, Competitive Landscape, Emerging Therapies 7Health News:InterAmerican College Announces Certification of Master of Science in Nursing - Family Nurse Practitioner Program 2Health News:InterAmerican College Announces Certification of Master of Science in Nursing - Family Nurse Practitioner Program 3Health News:Key Leadership Seminar: Maximizing Profit through Social Intelligence - What Neuroscience Tells Us 2Health News:GlobalSign Releases Code Signing Certificates for Individual Software Developers 2Health News:GlobalSign Releases Code Signing Certificates for Individual Software Developers 3
The Benchmark Microplate Reader, with its increased wavelength range of 340 to 750 nm and high performance optics, provides flexibility for specialized applications requiring increased linearity, ult...
Elisa strip reader...
Iems Incubator/Shaker expansion module for 2 module incubator/shaker. high performance microplate incubator and orbital shaker. It's superior temperature control and efficient orbital shaking reduce ...
... Millennium 2000 is a unique microprocessor controlled ... microplates in either 96 or 384 well ... via the control panel and all are ... visible under the clear protective cover. The ...
Medicine Products: